Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,132.57 -273.09 (-0.71%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,144.13 -2.90 (-0.04%) Bitcoin USD
59,846.30 -4,497.86 (-6.99%) CMC Crypto 200
1,289.33 -49.73 (-3.71%)
Adial Pharmaceuticals, Inc. (ADIL)
After hours:
| Previous close | 1.6900 |
| Open | 1.6900 |
| Bid | 1.6800 x 200 |
| Ask | 1.7400 x 200 |
| Day's range | 1.6600 - 1.7700 |
| 52-week range | 0.7700 - 14.0000 |
| Volume | |
| Avg. volume | 6,524,359 |
| Market cap | 6.893M |
| Beta (5Y monthly) | 1.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.9100 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.00 |
BenzingaEXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc (NASDAQ:ADIL). This patent expands Adial’s intellectual property protection and covers the combination of the company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the company’s lead investigational new drug pr
GlobeNewswireAdial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial’s intellectual property protection and covers the combination of the Company’s proprietary g
- GlobeNewswire
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trialGLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high c
